CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 33 enrolled
Drug / intervention
Sitagliptin +1 moredrug
Likely dose
Sitagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01112670
NCT01112670Phase 4Completed
CompareCT.gov

The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology

University of Colorado, Denver·interventional·Posted Apr 28, 2010·Updated Jan 24, 2013

In Brief

A Phase 4 clinical trial evaluating Sitagliptin and atorvastatin for Healthy. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the pharmacogenetics, pharmacokinetics, and drug-drug interactions of sitagliptin therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 28, 2010
Enrollment StartNov 1, 2009
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.2 years ago

Interventions

Sitagliptindrug

sitagliptin 100 mg x 1 dose

atorvastatindrug

atorvastatin 40 mg x 5 doses